ENDP

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MONTREAL, Oct. 22, 2020 /CNW/ -- Paladin Labs Inc.

MONTREAL, Oct. 22, 2020 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), announced today that Ontario, Quebec, Manitoba and Saskatchewan now

BRIDGEWATER, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food

BRIDGEWATER, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation. Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product. This is the first approval under the previously announced collaboration between Nevakar and Endo for the development of five differentiated, sterile injectable products in the U.S. and Canada. Under the terms of the agreement, Nevakar has responsibility to develop and obtain FDA approval for these products and Par Pharmaceuticals’ Sterile Products division will launch and distribute the products.“We are pleased to have received approval for this convenient, patent pending, ready-to-use form of a frequently used treatment for clinically important hypotension during anesthesia. We value our strong partnership with Endo, a respected pharmaceutical company with a significant and growing presence in sterile and critical care products as we pursue our mission to develop innovative pharmaceutical products that improve patient care and quality of life,” stated Navneet Puri, Ph.D., Founder, Chairman and Chief Executive Officer of Nevakar.About Nevakar Inc. Nevakar Inc. is growing as a fully integrated biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater New Jersey, the Company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop, and obtain regulatory approval for its products. Additional information is available at www.nevakar.com.Investor Contacts:Marshall Woodworth Chief Financial Officer (908) 625-3547 E: mwoodworth@nevakar.comLisa M. Wilson (212) 452-2793 E: lwilson@insitecony.com

Privately held Purdue Pharma, the corporate poster child in the opioid epidemic due to its aggressive promotion of pain pill OxyContin, has agreed to plead guilty to three criminal charges

Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)